Sensus Healthcare CEO buys 20K shares at $3.0243

Sensus Healthcare, Inc. (SRTS) reported that its Chief Executive Officer and director, Joseph C. Sardano, purchased 20,000 shares of common stock on 2026-08-20 in an open-market or private transaction at $3.0243 per share.

Rhea-AI Filing Summary

Sensus Healthcare, Inc. (SRTS) reported that its Chief Executive Officer and director, Joseph C. Sardano, purchased 20,000 shares of common stock on 2026-08-20 in an open-market or private transaction at $3.0243 per share. Following this transaction, he directly owns 1,220,293 shares of SRTS common stock.

Insider Trade Summary

Net Buyer: 20,000 shares

Net Buy 1 txn

Insider Sardano Joseph C

Role CHIEF EXECUTIVE OFFICER

Bought 20,000 shs ($60K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	20,000	$3.0243	$60K

Holdings After Transaction: Common Stock — 1,220,293 shares (Direct)

Key Figures

Shares purchased: 20,000 shares of Common Stock Purchase price per share: $3.0243 per share Shares owned after transaction: 1,220,293 shares +1 more

4 metrics

Shares purchased 20,000 shares of Common Stock Purchase on 2026-08-20 reported on Form 4

Purchase price per share $3.0243 per share Open-market or private transaction on 2026-08-20

Shares owned after transaction 1,220,293 shares Direct ownership by Joseph C. Sardano following the trade

Net buy shares 20,000 shares Net effect of reported transactions in this Form 4

Key Terms

Form 4, Common Stock, Rule 10b5-1

3 terms

Form 4 regulatory

"reported on Form 4"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Rule 10b5-1 regulatory

"indicates the Rule 10b5-1 checkbox is not affirmed"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Sensus Healthcare (SRTS) report for Joseph C. Sardano?

Sensus Healthcare reported that CEO and director Joseph C. Sardano purchased 20,000 shares of SRTS common stock on 2026-08-20 in an open-market or private transaction at $3.0243 per share, bringing his direct holdings to 1,220,293 shares.

How many SRTS shares does Joseph C. Sardano own after this Form 4 transaction?

After the reported transaction, Joseph C. Sardano directly owns 1,220,293 shares of Sensus Healthcare, Inc. common stock. This figure includes the 20,000 shares he purchased on 2026-08-20 at $3.0243 per share.

At what price did the SRTS CEO buy shares in the latest Form 4 filing?

The Sensus Healthcare CEO, Joseph C. Sardano, purchased 20,000 shares of SRTS common stock at a price of $3.0243 per share on 2026-08-20, in an open-market or private transaction reported on Form 4.

Was the recent SRTS insider trade by Joseph C. Sardano a purchase or a sale?

The reported insider trade by Joseph C. Sardano was a purchase. He acquired 20,000 shares of Sensus Healthcare common stock on 2026-08-20 at $3.0243 per share, increasing his direct ownership to 1,220,293 shares.

Was the SRTS CEO’s Form 4 transaction under a Rule 10b5-1 trading plan?

The filing indicates the Rule 10b5-1 checkbox is not affirmed (set to false), meaning the reported 20,000-share purchase by CEO Joseph C. Sardano on 2026-08-20 was not stated to be pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/24/2026 - 04:00 PM Accepted by SEC EDGAR 08/24/2026 - 04:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sardano Joseph C

(Last) (First) (Middle)

851 BROKEN SOUND PARKWAY NW STE 215

(Street)

BOCA RATON FLORIDA 33487

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sensus Healthcare, Inc. [ SRTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/20/2026		P		20,000	A	$3.0243	1,220,293	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ /s/ Joseph C. Sardano	08/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)